scholarly journals Analysis of ROC: The value of HPV16 E6 protein in the diagnosis of early stage cervical carcinoma and precancerous lesions

2016 ◽  
Vol 12 (3) ◽  
pp. 1769-1772 ◽  
Author(s):  
Li Sun ◽  
Shubin Xu ◽  
Lei Liang ◽  
Liang Zhao ◽  
Lei Zhang
Keyword(s):  
Cervical Carcinoma ◽  
Early Stage ◽  
Precancerous Lesions ◽  
Hpv16 E6 ◽  
E6 Protein

In silico approach for designing a novel recombinant fusion protein as a Candidate Vaccine against HPV

2020 ◽  
Vol 17 ◽  
Author(s):  
Mohsen Sisakht ◽  
Amir Mahmoodzadeh ◽  
Mohammadsaeid Zahedi ◽  
Davood Rostamzadeh ◽  
Amin Moradi Hasan-Abad ◽  
...  
Keyword(s):  
Immune Responses ◽  
Fusion Protein ◽  
In Silico ◽  
Precancerous Lesions ◽  
Candidate Vaccine ◽  
T Cell Epitopes ◽  
Binding Interaction ◽  
Hpv16 E6 ◽  
E7 Proteins

Background: Human papillomavirus (HPV) is the main biological agent causing sexually transmitted diseases (STDs), including precancerous lesions and several types of prevalent cancers. To date, numerous types of vaccines are designed to prevent high-risk HPV. However, their prophylactic effect is not the same and does not clear previous infections. Therefore, there is an urgent need for developing therapeutic vaccines that trigger cell-mediated immune responses for the treatment of HPV. The HPV16 E6 and E7 proteins are ideal targets for vaccine therapy against HPV. Fusion protein vaccines, which include both immunogenic interest protein and an adjuvant for augmenting the immunogenicity effects, are theoretically capable of guarantee the power of the immune system against HPV. Method: A vaccine construct, including HPV16 E6/E7 proteins along with a heat shock protein GP96 (E6/E7-NTGP96 construct), was designed using in silico methods. By the aid of the SWISS-MODEL server, the optimal 3D model of the designed vaccine was selected, followed by physicochemical and molecular parameters were performed using bioinformatics tools. Docking studies were done to evaluate the binding interaction of the vaccine. Allergenicity, immunogenicity, B, and T cell epitopes of the designed construct were predicted. Results: Immunological and structural computational results illustrated that our designed construct is potentially proper for stimulation of cellular and humoral immune responses against HPV. Conclusion: Computational studies showed that the E6/E7-NTGP96 construct is a promising candidate vaccine that needs further in vitro and in vivo evaluations.

Immunohistochemical expression of p53, bcl-2, and p21WAF1/CIP1 in early cervical carcinoma: Correlation with clinical outcome

2002 ◽  
Vol 12 (3) ◽  
pp. 290-298 ◽  
Author(s):  
M Graflund ◽  
B Sorbe ◽  
M Karlsson
Keyword(s):  
Survival Rate ◽  
Clinical Outcome ◽  
Cervical Carcinoma ◽  
Early Stage ◽  
Tumor Grade ◽  
Figo Stage ◽  
Immunohistochemical Expression ◽  
Cancer Specific Survival ◽  
Term Survival ◽  
Cervical Carcinomas

Abstract.Graflund M, Sorbe B, Karlsson M. Immunohistochemical expression of p53, bcl-2, and p21 WAF1/CIP1 in early cervical carcinoma: Correlation with clinical outcome.The objective of this study was to assess the value of p53, bcl-2, and p21WAF1/CIP1 immunoreactivity as predictors of pelvic lymph node metastases (LNM), recurrences, and death due to the disease in early stage (FIGO I-II) cervical carcinomas. FIGO stage, type of histopathology, and tumor grade were also evaluated in this series of patients treated by radical hysterectomy (Wertheim-Meigs) between 1965 and 1990. A total of 172 patients were included. A tumor was regarded as positive when more than 30% of the neoplastic cells exhibited immunoreactivity. Positive immunostaining was found in 8.9% for p53, in 43.5% for bcl-2, and in 25.0% for p21WAF1/CIP1. None of them was able to predict LNM or clinical outcome. Presence of LNM, tumor recurrence, and death from disease were significantly associated with the FIGO stage (P = 0.014, P = 0.009, and P = 0.001, respectively). The 5-year cancer-specific survival rate was 91.6% and the overall survival rate was 90.5%. It was concluded that immunohistochemically detected p53, bcl-2, and p21WAF1/CIP1 appeared to be of no predictive value with regard to LNM, tumor recurrences, or long-term survival in early cervical carcinomas.

scholarly journals Early-stage, high-grade neuroendocrine cervical carcinoma

2021 ◽  
Vol 31 (8) ◽  
pp. 1179-1183
Author(s):  
Gloria Salvo ◽  
Preetha Ramalingam ◽  
Priya Bhosale ◽  
Michael Frumovitz
Keyword(s):  
Cervical Carcinoma ◽  
Early Stage ◽  
High Grade

Adenocarcinoma as an independent risk factor for early-stage intermediate-risk cervical carcinoma

2011 ◽  
Vol 120 ◽  
pp. S104-S105
Author(s):  
C. Mathews ◽  
S. Goodrich ◽  
R. Farrell ◽  
C. DeSimone ◽  
L. Seamon ◽  
...  
Keyword(s):  
Risk Factor ◽  
Cervical Carcinoma ◽  
Independent Risk Factor ◽  
Early Stage ◽  
Intermediate Risk

Detection and quantitation of human papillomavirus DNA in primary tumour and lymph nodes of patients with early stage cervical carcinoma

2005 ◽  
Vol 33 (3) ◽  
pp. 201-205 ◽  
Author(s):  
Paul K.S. Chan ◽  
May M.Y. Yu ◽  
Tak-Hong Cheung ◽  
Ka-Fai To ◽  
Keith W.K. Lo ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Lymph Nodes ◽  
Cervical Carcinoma ◽  
Early Stage ◽  
Primary Tumour ◽  
Papillomavirus Dna

Short-time analysis for adjuvant chemotherapy in patients with early-stage bulky cervical carcinoma

2003 ◽  
Vol 15 (2) ◽  
pp. 144-148 ◽  
Author(s):  
Hua Linghu ◽  
Xiao-rong Xu ◽  
Yao-yu Mei ◽  
Jun-ying Tang ◽  
Liang-dan Tang ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Cervical Carcinoma ◽  
Early Stage ◽  
Time Analysis ◽  
Short Time

scholarly journals Does pretreatment HPV viral load correlate with prognosis in patients with early stage cervical carcinoma?

2008 ◽  
Vol 19 (2) ◽  
pp. 113 ◽  
Author(s):  
Yong Mi Kim ◽  
Jin Young Park ◽  
Kyung Mi Lee ◽  
Tae-Wook Kong ◽  
Seung-Chul Yoo ◽  
...  
Keyword(s):  
Viral Load ◽  
Cervical Carcinoma ◽  
Early Stage ◽  
Hpv Viral Load

scholarly journals Diagnostic value of macrophage inhibitory cytokine 1 as a novel prognostic biomarkers for early gastric cancer screening

2020 ◽  
Author(s):  
Xin Ge ◽  
Xiaolei Zhang ◽  
Yanling Ma ◽  
Shaohua Chen ◽  
Zhaowu Chen ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Early Gastric Cancer ◽  
Cancer Diagnosis ◽  
Early Stage ◽  
Precancerous Lesions ◽  
Diagnostic Value ◽  
Low Grade ◽  
Serum Samples ◽  
Early Screening ◽  
Roc Curve Analysis

Abstract BACKGROUND Early diagnosis is very important to improve the survival rate of patients with gastric cancer, especially in asymptomatic participants. However, low sensitivity of common biomarkers has caused difficulties in early screening of gastric cancer. In this study, we explored whether MIC-1 can improve the detection rate of early gastric cancer.METHODS We screened 8,257 participants based on risk factors such as age, gender, and family history for physical examination including gastroscopy. Participant blood samples were taken for measure MIC-1, CA-199, CA72-4 and PG1/PG2 levels. The diagnostic performance of MIC-1 was assessed and compared with CA-199, CA72-4 and PG1/PG2, and its role in early gastric cancer diagnosis and the assessment of the risk of precancerous lesions have also been studied.RESULTS Based on endoscopic and histopathological findings, 55 participants had gastric cancer, 566 participants had low-grade neoplasia, 2605 participants had chronic gastritis. MIC-1 levels were significantly elevated in gastric cancer serum samples as compared to controls (p<0.001). The sensitivity of serum MIC-1 for gastric cancer diagnosis was much higher than that of CA-199 (49.1% vs. 20.0%) with similar specificities. Moreover, receiver operating characteristic (ROC) curve analysis also showed that serum MIC-1 had a better performance compared with CA-199, CA72-4 and PG1/PG2 in distinguishing early-stage gastric cancer (AUC: 72.9% vs. 69.5%, 67.5%, 44.0% respectively).CONCLUSIONS Serum MIC-1 is significantly elevated in most patients with early gastric cancer. MIC-1 can serve as a novel diagnostic marker of early gastric cancer and value the risk of gastric cancer.

scholarly journals HypermethylatedFAM5CandMYLKin Serum as Diagnosis and Pre-Warning Markers for Gastric Cancer

2012 ◽  
Vol 32 (3) ◽  
pp. 195-202 ◽  
Author(s):  
Lu Chen ◽  
Liping Su ◽  
Jianfang Li ◽  
Yanan Zheng ◽  
Beiqin Yu ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Candidate Genes ◽  
Early Stage ◽  
Precancerous Lesions ◽  
Single Gene ◽  
High Specificity ◽  
Serum Samples ◽  
Promoter Regions ◽  
Gastric Cancer Cell Lines ◽  
Combined Detection

Most cases of gastric cancer (GC) are not diagnosed at early stage which can be curable, so it is necessary to identify effective biomarkers for its diagnosis and pre-warning. We have used methylated DNA immunoprecipitation (MeDIP) to identify genes that are frequently methylated in gastric cancer cell lines. Promoter regions hypermethylation of candidate genes were tested by methylation-specific polymerase chain reaction (MSP) in serum samples, including GC (n= 58), gastric precancerous lesions (GPL,n= 46), and normal controls (NC,n= 30). Eighty two hypermethylated genes were acquired by array analysis and 5 genes (BCAS4, CHRM2, FAM5C, PRACandMYLK) were selected as the candidate genes. Three genes (CHRM2, FAM5CandMYLK) were further confirmed to show methylation rates increased with progression from NC to GPL, then to GC. There was obvious decrease in detection ofFAM5CandMYLKhypermethylation, but notCHRM2, from preoperative to postoperative evaluation (P< 0.001). Combined detection of FAM5C and MYLK hypermethylation had a higher sensitivity in GC diagnosis (77.6%,45/58) and pre-warning (30.4%,14/46) than one single gene detection and also had a high specificity of 90%. The combined hypermethylated status ofFAM5CandMYLKcorrelated with tumor size (P< 0.001), tumor invasion depth (P= 0.001) and tumor-node-metastasis (TNM) stage (P= 0.003). HypermethylatedFAM5CandMYLKcan be used as potential biomarkers for diagnosis and pre-warning of GC.

Abstract 168: The significance of squamous vs. adenocarcinoma subtypes in early-stage cervical carcinoma.

2013 ◽  
Author(s):  
Ira Winer ◽  
Isabel Alvarado-Cabrero ◽  
Shelly Seward ◽  
Raquel Valencia-Cedillo ◽  
Adnan Munkarah ◽  
...  
Keyword(s):  
Cervical Carcinoma ◽  
Early Stage
Sign in / Sign up

Export Citation Format

Share Document